Emoxypine

Emoxypine

SCHEMBL1010987

CCc1nc(C)ccc1O.O=C(O)CCC(=O)O

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4

The experimentally established mechanism targets of Emoxypine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.56
ALDH1A1 P00352 6/20 0.56
HPGD P15428 4/20 0.51
HSD17B10 Q99714 2/20 0.51
USP2 O75604 1/20 0.51
GFER P55789 1/20 0.46
RAB9A P51151 4/20 0.42
GAA P10253 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
KMT2A Q03164 8/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Emoxypine SCHEMBL30182715 1.00 KDM4E (0.56) KDM4EALDH1A1HPGDHSD17B10USP2
Emoxypine SCHEMBL195347 0.87 KDM4E (0.72) KDM4EALDH1A1HPGDHSD17B10USP2
Emoxypine SCHEMBL29362452 0.87 KDM4E (0.72) KDM4EALDH1A1HPGDHSD17B10USP2
Emoxypine SCHEMBL1373708 0.85 KDM4E (0.69) KDM4EALDH1A1HPGDHSD17B10USP2
Emoxypine SCHEMBL11089142 0.85 KDM4E (0.69) KDM4EALDH1A1HPGDHSD17B10USP2
Emoxypine SCHEMBL31074958 0.85 KDM4E (0.69) KDM4EALDH1A1HPGDHSD17B10USP2
Emoxypine SCHEMBL1373711 0.83 KDM4E (0.67) KDM4EALDH1A1HPGDHSD17B10USP2
Emoxypine SCHEMBL26983696 0.83 KDM4E (0.67) KDM4EALDH1A1HPGDHSD17B10USP2
Emoxypine SCHEMBL21061700 0.83 KDM4E (0.73) KDM4EALDH1A1HPGDHSD17B10USP2
Emoxypine SCHEMBL30377215 0.81 KDM4E (0.47) KDM4EALDH1A1HPGDHSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021242136-A1 DRUG FOR A COMBINATION THERAPY FOR DISEASES CAUSED BY BETACORONAVIRUSES ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НАУЧНО-ПРОИЗВОДСТВЕННАЯ КОМПАНИЯ "ФАРМАСОФТ" 2021-12-02 WO claimed
WO-2021118403-A1 SYSTEM FOR DELIVERING 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE SUCCINATE FOR PERORAL ADMINISTRATION ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НАУЧНО-ПРОИЗВОДСТВЕННАЯ КОМПАНИЯ "ФАРМАСОФТ" 2021-06-17 WO claimed
WO-2025023864-A1 METHOD FOR TREATING TRAUMATIC BRAIN INJURY AND DRUG FOR CARRYING OUT SAID METHOD Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) 2025-01-30 WO disclosed
WO-2022055397-A1 METHOD FOR PRODUCING A DRUG FOR PARENTERAL ADMINISTRATION ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НАУЧНО-ТЕХНОЛОГИЧЕСКАЯ ФАРМАЦЕВТИЧЕСКАЯ ФИРМА "ПОЛИСАН" 2022-03-17 WO disclosed
WO-2021242136-A1 DRUG FOR A COMBINATION THERAPY FOR DISEASES CAUSED BY BETACORONAVIRUSES ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НАУЧНО-ПРОИЗВОДСТВЕННАЯ КОМПАНИЯ "ФАРМАСОФТ" 2021-12-02 WO disclosed
WO-2021242136-A1 DRUG FOR A COMBINATION THERAPY FOR DISEASES CAUSED BY BETACORONAVIRUSES ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НАУЧНО-ПРОИЗВОДСТВЕННАЯ КОМПАНИЯ "ФАРМАСОФТ" 2021-12-02 WO disclosed
WO-2021118403-A1 SYSTEM FOR DELIVERING 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE SUCCINATE FOR PERORAL ADMINISTRATION ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НАУЧНО-ПРОИЗВОДСТВЕННАЯ КОМПАНИЯ "ФАРМАСОФТ" 2021-06-17 WO disclosed
WO-2021118403-A1 SYSTEM FOR DELIVERING 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE SUCCINATE FOR PERORAL ADMINISTRATION ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НАУЧНО-ПРОИЗВОДСТВЕННАЯ КОМПАНИЯ "ФАРМАСОФТ" 2021-06-17 WO disclosed
WO-2019117820-A1 L-ENANTIOMER 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINIUM L-HYDROXYBUTANDIOATE WITH CEREBROPROTECTIVE, HEPATOPROTECTIVE, LIPID-REGULATING, ANTI-ISCHEMIC AND NEUROTROPIC ACTIVITIES MADMIT TRADE, A. S. (SK) 2019-06-20 WO disclosed
WO-2014070038-A1 SOLID DOSAGE FORM HAVING NEUROPROTECTIVE, ANTIAMNESIC, ANTIOXIDANT, ANTIHYPOXIC AND ANTI-ISCHEMIC ACTIVITY (VARIANTS) LOBKO VLADIMIR PAVLOVICH (RU) 2014-05-08 WO disclosed
WO-2014012593-A1 ALKYL SUBSTITUTED 3-HYDROXYPYRIDINES FOR THE TREATMENT OF DEPRESSION HandelsOrt AG (CH) 2014-01-23 WO disclosed
WO-2013129977-A2 PHARMACEUTICAL COMPOSITION FOR INJECTIONS HAVING NEUROPROTECTOR, ANTIAMNAESIC, ANTIOXIDANT, ANTIHYPOXIC AND ANTIISCHAEMIC ACTIVITY (EMBODIMENTS) LOBKO VLADIMIR PAVLOVICH (RU) 2013-09-06 WO disclosed
EP-1878431-B1 MEDICINAL AGENT FOR PREVENTING PROGRESSION OF APOPTOTIC AND JUGULATING NECROTIC CHANGES IN THE ORGANISM TISSUES OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU N PROIZV KOMPANIA FARMASOFT (RU) 2011-04-06 EP disclosed
EP-1789026-B1 METHOD FOR SYSTEMIC BIO-CORRECTION OF AN ORGANISM INST MOLEKULAR UND (DE) 2011-01-05 EP disclosed
EP-1878431-A1 MEDICINAL AGENT FOR PREVENTING PROGRESSION OF APOPTOTIC AND JUGULATING NECROTIC CHANGES IN THE ORGANISM TISSUES Sukoyan, Galina Victorovna (RU) 2008-01-16 EP disclosed
EP-1789026-A2 METHOD FOR SYSTEMIC BIO-CORRECTION OF AN ORGANISM Institut für Molekular und (DE) 2007-05-30 EP disclosed
WO-2006007818-A2 METHOD FOR SYSTEMIC BIO-CORRECTION OF AN ORGANISM INSTITUT FÜR MOLEKULAR- UND SYSTEM-MEDIZIN (DE) 2006-01-26 WO disclosed
EP-1380310-A1 Wound dressing Filatov, Vladimir N. (RU) 2004-01-14 EP disclosed
US-6500799-B2 Wound dressing FILATOV VLADIMIR N (RU) 2002-12-31 US disclosed
US-20020012692-A1 Wound dressing FILATOV VLADIMIR N (RU) 2002-01-31 US disclosed